Drug Profile


Alternative Names: CG 4203; SE 63

Latest Information Update: 20 Mar 1997

Price : $50

At a glance

  • Originator Grunenthal
  • Class Antiplatelets; Benzoic acids; Prostaglandins
  • Mechanism of Action Prostacyclin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arterial occlusive disorders; Coronary artery restenosis; Intermittent claudication; Myocardial infarction

Most Recent Events

  • 20 Mar 1997 Discontinued-II for Intermittent claudication (IV)
  • 20 Mar 1997 Discontinued-III for Arterial occlusive disorders in United Kingdom (Unknown route)
  • 20 Mar 1997 Discontinued-I for Intermittent claudication (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top